Impax Reports Third Quarter 2017 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Stocks fall as higher oil prices, Treasury yields weigh
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
Impax Laboratories (IPXL) PT Lowered to $16 at Cowen
November 10, 2017 8:15 AM ESTCowen lowered its price target on Impax Laboratories (NASDAQ: IPXL) to $16.00 (from $17.00) while maintaining a Market Perform rating. The Concerta delay and Renvela update were disappointing, but management is able to accelerate the previously announced cost reductions to partially offset this lack of... More
Impax Laboratories (IPXL) Tops Q3 EPS by 3c
November 9, 2017 7:05 AM ESTImpax Laboratories (NASDAQ: IPXL) reported Q3 EPS of $0.23, $0.03 better than the analyst estimate of $0.20. Revenue for the quarter came in at $206.4 million versus the consensus estimate of $208.36 million.
For earnings history and earnings-related data on Impax Laboratories (IPXL) click here.
... More